These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8018746)

  • 1. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes.
    Lozier JN; Thompson AR; Hu PC; Read M; Brinkhous KM; High KA; Curiel DT
    Hum Gene Ther; 1994 Mar; 5(3):313-22. PubMed ID: 8018746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.
    Axelrod JH; Read MS; Brinkhous KM; Verma IM
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5173-7. PubMed ID: 2367529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors.
    Dai YF; Qiu XF; Xue JL; Liu ZD
    Sci China B; 1992 Feb; 35(2):183-93. PubMed ID: 1581003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene transfer to respiratory epithelial cells via the receptor-mediated endocytosis pathway.
    Curiel DT; Agarwal S; Rømer MU; Wagner E; Cotten M; Birnstiel ML; Boucher RC
    Am J Respir Cell Mol Biol; 1992 Mar; 6(3):247-52. PubMed ID: 1540389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient.
    Zhou JM; Dai YF; Qiu XF; Hou GY; Akira Y; Xue JL
    Sci China B; 1993 Sep; 36(9):1082-92. PubMed ID: 8274202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
    Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
    Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
    Larson PJ; High KA
    Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro expression of hemophilia B gene mediated by lentivirus].
    Yan DM; Xu KL; Du B; Zeng LY; Lu QX; Pan XY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):583-6. PubMed ID: 19175982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
    Kay MA; Landen CN; Rothenberg SR; Taylor LA; Leland F; Wiehle S; Fang B; Bellinger D; Finegold M; Thompson AR
    Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2353-7. PubMed ID: 8134398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
    Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
    Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer as an approach to cure patients with hemophilia A or B.
    Thompson AR; Palmer TD; Lynch CM; Miller AD
    Curr Stud Hematol Blood Transfus; 1991; (58):59-62. PubMed ID: 1954775
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficient gene transfer to dispersed human pancreatic islet cells in vitro using adenovirus-polylysine/DNA complexes or polycationic liposomes.
    Saldeen J; Curiel DT; Eizirik DL; Andersson A; Strandell E; Buschard K; Welsh N
    Diabetes; 1996 Sep; 45(9):1197-203. PubMed ID: 8772722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.
    Brooks MB; Gu W; Barnas JL; Ray J; Ray K
    Mamm Genome; 2003 Nov; 14(11):788-95. PubMed ID: 14722728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term expression of human factor IX cDNA in rabbits.
    Zhou JM; Qiu XF; Lu DR; Lu JY; Xue JL
    Sci China B; 1993 Nov; 36(11):1333-41. PubMed ID: 8142022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.